AMGN34:BVMF
Amgen Inc. BDR
91,80 BRL
arrow_downward
−1,46%(−1,36) 1D
11. stu, 10:41:17 GMT -3 · BRL
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za AMGN34...
Otvori
92,38 BRL
Najviša
92,38 BRL
Najniža
91,80 BRL
Trž. kap.
249,08 mlr.
Prosj. kol.
307,00
Količina
9,00
52-tjed. najviša
94,72 BRL
52-tjed. najniža
47,76 BRL
Dionice u optjecaju
540,91 mil.
Broj djelatnika
32 tis.
Otvori
92,38 BRL
Najviša
92,38 BRL
Najniža
91,80 BRL
Trž. kap.
249,08 mlr.
Prosj. kol.
307,00
Količina
9,00
52-tjed. najviša
94,72 BRL
52-tjed. najniža
47,76 BRL
Dionice u optjecaju
540,91 mil.
Broj djelatnika
32 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Reuters
·
prije 55 minuta
Amgen's Sjogren's drug cuts disease activity in trial
Investing.com
·
prije 1 sat
Amgen reports positive phase 3 trial results for Sjögren’s treatment
Investor's Business Daily
·
prije 2 sata
How Amgen, In A Buy Zone, Is Taking On Novartis With A First-Ever
Trefis
·
prije 4 sata
Is Amgen Stock Too Dependent On Six Growth Drivers?
Profil
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Amgen Inc. BDR – informacije
Glavni izvršni direktorRobert A. Bradway
Zaposlenici31,5 tis.
Osnovano1980
SjedišteThousand Oaks, Kalifornija, Sjedinjene Američke Države
SektorHealth Care
Djelatnost-
Web-lokacijaamgen.com